Photodynamic Therapy of Established Prostatic Adenocarcinoma with TOOKAD: A Biphasic Apparent Diffusion Coefficient Change as Potential Early MRI Response Marker
The goal of this study was to examine the use of diffusion-weighted magnetic resonance imaging (DW-MRI) for the assessment of early progression of photodamage induced by Pd-bacteriopheophorbide (TOOKAD)-based photodynamic therapy (PDT). TOOKAD is a novel second-generation photosensitizer for PDT of...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2004-05-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1476558604800691 |
id |
doaj-6bc983fc0fbb4b42b9f835664e7070fb |
---|---|
record_format |
Article |
spelling |
doaj-6bc983fc0fbb4b42b9f835664e7070fb2020-11-24T21:02:29ZengElsevierNeoplasia: An International Journal for Oncology Research1476-55861522-80022004-05-016322423310.1593/neo.03352Photodynamic Therapy of Established Prostatic Adenocarcinoma with TOOKAD: A Biphasic Apparent Diffusion Coefficient Change as Potential Early MRI Response MarkerVicki Plaks0Natalia Koudinova1Uri Nevo2Jehonathan H. Pinthus3Hannah Kanety4Zelig Eshhar5Jacob Ramon6Avigdor Scherz7Michal Neeman8Yoram Salomon9Department of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, IsraelDepartment of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, IsraelDepartments of Neurobiology, The Weizmann Institute of Science, Rehovot 76100, IsraelDepartment of Immunology, The Weizmann Institute of Science, Rehovot 76100, IsraelDepartment of The Institute of Endocrinology, Sheba Medical Center, Tel Hashomer 52621, IsraelDepartment of Immunology, The Weizmann Institute of Science, Rehovot 76100, IsraelDepartment of Urology, Sheba Medical Center, Tel Hashomer 52621, IsraelDepartment of Plant Sciences, The Weizmann Institute of Science, Rehovot 76100, IsraelDepartment of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, IsraelDepartment of Biological Regulation, The Weizmann Institute of Science, Rehovot 76100, Israel The goal of this study was to examine the use of diffusion-weighted magnetic resonance imaging (DW-MRI) for the assessment of early progression of photodamage induced by Pd-bacteriopheophorbide (TOOKAD)-based photodynamic therapy (PDT). TOOKAD is a novel second-generation photosensitizer for PDT of solid tumors developed in our laboratory and presently under clinical trials for prostate cancer (PC) therapy. Using the subcutaneous human prostate adenocarcinoma WISH-PC14 xenografts in nude mice as a model, a unique biphasic change in the apparent diffusion coefficient (ADC) was observed within the first 24 hours post-PDT, with initial decrease followed by an increase in ADC. Using DW-MRI, this phenomenon enables the detection of successful tumor response to PDT within 7 hours posttreatment. This process was validated by direct, histological, immunohistochemical examinations and also by evaluation of serum prostate-specific antigen (PSA) levels that decreased significantly already 7 hours posttreatment. In vitro studies of multicellular cell spheroids confirmed a PDT-induced decrease in ADC, suggesting that lipid peroxidation (LPO) significantly contributes to ADC decline observed after PDT. These results demonstrate that TOOKAD-based PDT successfully eradicates prostate adenocarcinoma xenografts and suggests DW-MRI to be useful for the detection of early tumor response and treatment outcome in the clinical setting. http://www.sciencedirect.com/science/article/pii/S1476558604800691Diffusion MRIphotodynamic therapyhuman prostate adenocarcinomaTOOKADcell spheroid |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Vicki Plaks Natalia Koudinova Uri Nevo Jehonathan H. Pinthus Hannah Kanety Zelig Eshhar Jacob Ramon Avigdor Scherz Michal Neeman Yoram Salomon |
spellingShingle |
Vicki Plaks Natalia Koudinova Uri Nevo Jehonathan H. Pinthus Hannah Kanety Zelig Eshhar Jacob Ramon Avigdor Scherz Michal Neeman Yoram Salomon Photodynamic Therapy of Established Prostatic Adenocarcinoma with TOOKAD: A Biphasic Apparent Diffusion Coefficient Change as Potential Early MRI Response Marker Neoplasia: An International Journal for Oncology Research Diffusion MRI photodynamic therapy human prostate adenocarcinoma TOOKAD cell spheroid |
author_facet |
Vicki Plaks Natalia Koudinova Uri Nevo Jehonathan H. Pinthus Hannah Kanety Zelig Eshhar Jacob Ramon Avigdor Scherz Michal Neeman Yoram Salomon |
author_sort |
Vicki Plaks |
title |
Photodynamic Therapy of Established Prostatic Adenocarcinoma with TOOKAD: A Biphasic Apparent Diffusion Coefficient Change as Potential Early MRI Response Marker |
title_short |
Photodynamic Therapy of Established Prostatic Adenocarcinoma with TOOKAD: A Biphasic Apparent Diffusion Coefficient Change as Potential Early MRI Response Marker |
title_full |
Photodynamic Therapy of Established Prostatic Adenocarcinoma with TOOKAD: A Biphasic Apparent Diffusion Coefficient Change as Potential Early MRI Response Marker |
title_fullStr |
Photodynamic Therapy of Established Prostatic Adenocarcinoma with TOOKAD: A Biphasic Apparent Diffusion Coefficient Change as Potential Early MRI Response Marker |
title_full_unstemmed |
Photodynamic Therapy of Established Prostatic Adenocarcinoma with TOOKAD: A Biphasic Apparent Diffusion Coefficient Change as Potential Early MRI Response Marker |
title_sort |
photodynamic therapy of established prostatic adenocarcinoma with tookad: a biphasic apparent diffusion coefficient change as potential early mri response marker |
publisher |
Elsevier |
series |
Neoplasia: An International Journal for Oncology Research |
issn |
1476-5586 1522-8002 |
publishDate |
2004-05-01 |
description |
The goal of this study was to examine the use of diffusion-weighted magnetic resonance imaging (DW-MRI) for the assessment of early progression of photodamage induced by Pd-bacteriopheophorbide (TOOKAD)-based photodynamic therapy (PDT). TOOKAD is a novel second-generation photosensitizer for PDT of solid tumors developed in our laboratory and presently under clinical trials for prostate cancer (PC) therapy. Using the subcutaneous human prostate adenocarcinoma WISH-PC14 xenografts in nude mice as a model, a unique biphasic change in the apparent diffusion coefficient (ADC) was observed within the first 24 hours post-PDT, with initial decrease followed by an increase in ADC. Using DW-MRI, this phenomenon enables the detection of successful tumor response to PDT within 7 hours posttreatment. This process was validated by direct, histological, immunohistochemical examinations and also by evaluation of serum prostate-specific antigen (PSA) levels that decreased significantly already 7 hours posttreatment. In vitro studies of multicellular cell spheroids confirmed a PDT-induced decrease in ADC, suggesting that lipid peroxidation (LPO) significantly contributes to ADC decline observed after PDT. These results demonstrate that TOOKAD-based PDT successfully eradicates prostate adenocarcinoma xenografts and suggests DW-MRI to be useful for the detection of early tumor response and treatment outcome in the clinical setting.
|
topic |
Diffusion MRI photodynamic therapy human prostate adenocarcinoma TOOKAD cell spheroid |
url |
http://www.sciencedirect.com/science/article/pii/S1476558604800691 |
work_keys_str_mv |
AT vickiplaks photodynamictherapyofestablishedprostaticadenocarcinomawithtookadabiphasicapparentdiffusioncoefficientchangeaspotentialearlymriresponsemarker AT nataliakoudinova photodynamictherapyofestablishedprostaticadenocarcinomawithtookadabiphasicapparentdiffusioncoefficientchangeaspotentialearlymriresponsemarker AT urinevo photodynamictherapyofestablishedprostaticadenocarcinomawithtookadabiphasicapparentdiffusioncoefficientchangeaspotentialearlymriresponsemarker AT jehonathanhpinthus photodynamictherapyofestablishedprostaticadenocarcinomawithtookadabiphasicapparentdiffusioncoefficientchangeaspotentialearlymriresponsemarker AT hannahkanety photodynamictherapyofestablishedprostaticadenocarcinomawithtookadabiphasicapparentdiffusioncoefficientchangeaspotentialearlymriresponsemarker AT zeligeshhar photodynamictherapyofestablishedprostaticadenocarcinomawithtookadabiphasicapparentdiffusioncoefficientchangeaspotentialearlymriresponsemarker AT jacobramon photodynamictherapyofestablishedprostaticadenocarcinomawithtookadabiphasicapparentdiffusioncoefficientchangeaspotentialearlymriresponsemarker AT avigdorscherz photodynamictherapyofestablishedprostaticadenocarcinomawithtookadabiphasicapparentdiffusioncoefficientchangeaspotentialearlymriresponsemarker AT michalneeman photodynamictherapyofestablishedprostaticadenocarcinomawithtookadabiphasicapparentdiffusioncoefficientchangeaspotentialearlymriresponsemarker AT yoramsalomon photodynamictherapyofestablishedprostaticadenocarcinomawithtookadabiphasicapparentdiffusioncoefficientchangeaspotentialearlymriresponsemarker |
_version_ |
1716775195490910208 |